JPRN-jRCT1080220387未知4 期
Post-Marketing Clinical Study of ReQuip Tablets in Patients with Parkinson's Disease -Evaluation of Long-Term Efficacy and Safety
GlaxoSmithKline K.K.0 个研究点目标入组 100 人开始时间: 2007年5月11日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main inclusion criteria:
- •- Patients with a diagnosis of PD (including juvenile parkinsonism) with Modified Hoehn & Yahr Stages I to IV.
- •- Patients who have been receiving another dopamine agonist for at least 4 weeks prior to the start of the screening phase and are expected to benefit from conversion to ReQuip.
- •- Age: >=20 years (at the time of written informed consent).
- •Main exclusion criteria:
- •- Patients who present with any serious medical condition other than PD (e.g., cardiac, hepatic or renal disorder or hematopoietic disorder).
- •- Patients with postural hypotension with any subjective symptoms (e.g., dizziness and syncope).
- •- Patients who have had any serious psychiatric symptoms (e.g., confusion, hallucination, delusion, abnormal behavior) (including symptoms caused by anti-PD drugs) within 6 months (26 weeks) prior to written informed consent.
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Post Market Clinical Follow-up study of the use of the vaginal cream Remifemin® FeuchtCreme (RFC)Complaints due to dryness of the vagina and the outer genital area (dry feeling, burning sensation, pain during sexual intercourse, or itching), as developed, for example, during the menopause.Facilitation of sexual intercourse.Physical support of the healing process of minor wounds and small inflammations of the vaginal skin.N89.8Other specified noninflammatory disorders of vaginaDRKS00006888Schaper & Brümmer GmbH & Co. KG230
已完成
不适用
Post-market clinical follow-up study evaluating the efficacy and safety of the wearable cardioverter-defibrillator (WCD) medical device 'LifeVest' in real-life settings in FranceISRCTN91372291ZO550
已完成
不适用
Post-market clinical follow-up investigation of the marketed Extended Range of Vision IOL (Intraocular lens)h25H26Senile cataractOther cataractDRKS00005742Abbott Medical Optics Inc.147
未知
4 期
Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) -Pharmacokinetic Study in HIV-Infected PatientsHIV infectionJPRN-jRCT1080220286GlaxoSmithKline K.K.
未知
4 期
A post-marketing clinical study of Aricept in patients with dementia with Lewy bodies (DLB)JPRN-jRCT1080222744Eisai Co., Ltd.140